{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:37:49Z","timestamp":1777574269165,"version":"3.51.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Deliv."],"abstract":"<jats:p>GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions which can deliver these peptides efficiently without requiring use of excessively high doses. This paper describes the ability of an oral peptide delivery formulation, Axcess\u2122, to enhance uptake of GLP-1 receptor agonists via the intestine, resulting in changes in insulin and glucose blood levels indicative of biopotencies of 9% for exendin-4 and 14.8% for semaglutide in preclinical models. The route of delivery suggests that the peptides will be able to interact with the GLP-1 receptors on the vagal afferents of the intestine, as is the case for native GLP-1 in healthy individuals. GLP-1 receptor agonists administered via this route will be a valuable addition to the therapeutic modalities available for treatment of diabetes and obesity.<\/jats:p>","DOI":"10.3389\/fddev.2024.1456654","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:48:59Z","timestamp":1730868539000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery"],"prefix":"10.3389","volume":"4","author":[{"given":"R. R. C.","family":"New","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bogus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. N.","family":"Travers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vaiceliunaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Burnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1016\/j.xphs.2019.04.022","article-title":"Quantifying the value of orally delivered biologic therapies: A\u00a0Cost-Effectiveness analysis of oral semaglutide","volume":"108","author":"Abramson","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control - a review","volume":"21","author":"Bain","year":"2018","journal-title":"Diabetes, Obes. Metabolism"},{"key":"B3","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e12643","DOI":"10.1111\/jne.12643","article-title":"The role of the vagus nerve in appetite control: implications for the pathogenesis of obesity","volume":"30","author":"Cork","year":"2018","journal-title":"J. Neuroendocrinol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by Exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model","volume":"16","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1463-1326.2009.01146.x","article-title":"The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes","volume":"12","author":"Luzio","year":"2009","journal-title":"Diabetes Obes. Metabolism"},{"key":"B9","unstructured":"Glucose sensing mediated by portal glucagon-like peptide 1 receptor is markedly impaired in insulin-resistant obese animals diabetes99110\n            MalbertC.-H.\n            ChauvinA.\n            HorowitzM.\n            JonesK. L.\n          10.2337\/db20-0361702021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/dom.14922","article-title":"Safety and efficacy of an oral insulin (capsulin) in patients with early-stage type 2 diabetes: a dose-ranging phase IIb study","author":"New","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical pharmacokinetics of oral semaglutide","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"22521","DOI":"10.1038\/s41598-021-01750-0","article-title":"Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease","volume":"11","author":"Pechenov","year":"2021","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"E1088","DOI":"10.1152\/ajpendo.00464.2009","article-title":"Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system","volume":"298","author":"Perez-Tilve","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B14","article-title":"Long-acting derivatives of glucagon like peptide-1 the endocrine society ENDO poster P2-45","author":"Peri","year":"2004"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"Rehfeld","year":"2018","journal-title":"J. Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2015.02.017","article-title":"Brain GLP-1 and insulin sensitivity","volume":"418","author":"Sandoval","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS","volume":"221","author":"van Bloemendaal","year":"2014","journal-title":"J. Endocrinol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41575-018-0062-1","article-title":"The metabolic role of vagal afferent innervation","volume":"15","author":"Waise","year":"2018","journal-title":"Nat. Rev. Gastroenterology and Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2016.05.011","article-title":"Sensory neurons that detect stretch and nutrients in the digestive system","volume":"166","author":"Williams","year":"2016","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2609","DOI":"10.1038\/cddis.2017.28","article-title":"Duodenal GLP-1 signaling regulates hepatic glucose production through a PKC-\u03b4-dependent neurocircuitry","volume":"8","author":"Yang","year":"2017","journal-title":"Cell Death Dis."}],"container-title":["Frontiers in Drug Delivery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2024.1456654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:49:02Z","timestamp":1730868542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2024.1456654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":21,"alternative-id":["10.3389\/fddev.2024.1456654"],"URL":"https:\/\/doi.org\/10.3389\/fddev.2024.1456654","relation":{},"ISSN":["2674-0850"],"issn-type":[{"value":"2674-0850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"article-number":"1456654"}}